Kevin Knopp - 908 Devices CEO, CoFounder
| MASS Stock | USD 4.16 0.05 1.19% |
Insider
Kevin Knopp is CEO, CoFounder of 908 Devices
| Age | 53 |
| Address | 645 Summer Street, Boston, MA, United States, 02210 |
| Phone | 857 254 1500 |
| Web | https://908devices.com |
Kevin Knopp Latest Insider Activity
Tracking and analyzing the buying and selling activities of Kevin Knopp against 908 Devices stock is an integral part of due diligence when investing in 908 Devices. Kevin Knopp insider activity provides valuable insight into whether 908 Devices is net buyers or sellers over its current business cycle. Note, 908 Devices insiders must abide by specific rules, including filing SEC forms every time they buy or sell 908 Devices'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Kevin Knopp over three months ago Disposition of 47418 shares by Kevin Knopp of 908 Devices at 1.75 subject to Rule 16b-3 | ||
Kevin Knopp over three months ago Disposition of 110626 shares by Kevin Knopp of 908 Devices at 1.58 subject to Rule 16b-3 | ||
Kevin Knopp over six months ago Disposition of 47000 shares by Kevin Knopp of 908 Devices at 1.75 subject to Rule 16b-3 | ||
Kevin Knopp over a year ago Exercise or conversion by Kevin Knopp of 11255 shares of 908 Devices subject to Rule 16b-3 |
908 Devices Management Efficiency
The company has return on total asset (ROA) of (0.1675) % which means that it has lost $0.1675 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5156) %, meaning that it created substantial loss on money invested by shareholders. 908 Devices' management efficiency ratios could be used to measure how well 908 Devices manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.6 in 2025. Return On Capital Employed is likely to gain to -0.54 in 2025. At this time, 908 Devices' Total Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 207.8 M in 2025, whereas Other Assets are likely to drop slightly above 962.9 K in 2025.Similar Executives
| Showing other executives | INSIDER Age | ||
| Charles Brynelsen | Abbott Laboratories | 63 | |
| Sally Saba | Medtronic PLC | N/A | |
| S Phanstiel | Butterfly Network | 62 | |
| Elaine Leavenworth | Abbott Laboratories | 65 | |
| Lisa Tatum | Stryker | 53 | |
| Paul Flynn | DexCom Inc | 55 | |
| Preston Wells | Stryker | N/A | |
| Randel Woodgrift | Abbott Laboratories | 59 | |
| Michael Carter | Nevro Corp | 52 | |
| Spencer Stiles | Stryker | 48 | |
| Yair Malca | InMode | 46 | |
| Diane Biagianti | Glaukos Corp | 64 | |
| Christopher Calamari | Abbott Laboratories | 50 | |
| Catherine Jennings | Boston Scientific Corp | N/A | |
| Andrea Wainer | Abbott Laboratories | 55 | |
| Vance Brown | Boston Scientific Corp | 55 | |
| Nava TalLauner | InMode | ||
| Stacey Pugh | Butterfly Network | 48 | |
| Julie Dewey | Nevro Corp | 63 | |
| Laverne Council | CONMED | 59 | |
| Kevin Lofton | Medtronic PLC | 65 | |
Management Performance
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.17 |
908 Devices Leadership Team
Elected by the shareholders, the 908 Devices' board of directors comprises two types of representatives: 908 Devices inside directors who are chosen from within the company, and outside directors, selected externally and held independent of 908. The board's role is to monitor 908 Devices' management team and ensure that shareholders' interests are well served. 908 Devices' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, 908 Devices' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kevin Knopp, CEO, CoFounder | ||
| Joseph IV, CFO Treasurer | ||
| Steve Araiza, CoFounder | ||
| Scott Miller, Cofounder Engineering | ||
| JD Esq, Chief Secretary | ||
| Christopher Brown, CoFounder Officer | ||
| Andrew Bartfay, CoFounder Development | ||
| Trent Basarsky, VP Devel | ||
| Michael Jobin, CoFounder Development | ||
| Maura Fitzpatrick, VP Marketing | ||
| Don Osmer, Vice Resources | ||
| Barbara Russo, VP Communications |
908 Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is 908 Devices a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (1.21) % | ||||
| Operating Margin | (0.56) % | ||||
| Current Valuation | 85.57 M | ||||
| Shares Outstanding | 35.33 M | ||||
| Shares Owned By Insiders | 8.00 % | ||||
| Shares Owned By Institutions | 63.48 % | ||||
| Number Of Shares Shorted | 2.28 M | ||||
| Price To Book | 1.30 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for 908 Stock Analysis
When running 908 Devices' price analysis, check to measure 908 Devices' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 908 Devices is operating at the current time. Most of 908 Devices' value examination focuses on studying past and present price action to predict the probability of 908 Devices' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 908 Devices' price. Additionally, you may evaluate how the addition of 908 Devices to your portfolios can decrease your overall portfolio volatility.